SMMT - Summit Therapeutics raises $200M; expands license territories for ivonescimab
2024-06-03 06:18:24 ET
More on Summit Therapeutics
- Summit Therapeutics Stock: Plunging Despite A Win?
- Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
- Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
- Summit lead asset approved in China for lung cancer
- Summit pares gains as ‘China-only’ trial beats Merck’s Keytruda (update)